1. Home
  2. CTNM vs ACNT Comparison

CTNM vs ACNT Comparison

Compare CTNM & ACNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • ACNT
  • Stock Information
  • Founded
  • CTNM 2009
  • ACNT 1945
  • Country
  • CTNM United States
  • ACNT United States
  • Employees
  • CTNM N/A
  • ACNT N/A
  • Industry
  • CTNM
  • ACNT Steel/Iron Ore
  • Sector
  • CTNM
  • ACNT Industrials
  • Exchange
  • CTNM Nasdaq
  • ACNT Nasdaq
  • Market Cap
  • CTNM 142.3M
  • ACNT 122.5M
  • IPO Year
  • CTNM 2024
  • ACNT N/A
  • Fundamental
  • Price
  • CTNM $5.77
  • ACNT $12.96
  • Analyst Decision
  • CTNM Strong Buy
  • ACNT
  • Analyst Count
  • CTNM 4
  • ACNT 0
  • Target Price
  • CTNM $22.50
  • ACNT N/A
  • AVG Volume (30 Days)
  • CTNM 366.4K
  • ACNT 96.0K
  • Earning Date
  • CTNM 08-12-2025
  • ACNT 08-05-2025
  • Dividend Yield
  • CTNM N/A
  • ACNT N/A
  • EPS Growth
  • CTNM N/A
  • ACNT N/A
  • EPS
  • CTNM N/A
  • ACNT N/A
  • Revenue
  • CTNM N/A
  • ACNT $174,652,000.00
  • Revenue This Year
  • CTNM N/A
  • ACNT $22.72
  • Revenue Next Year
  • CTNM N/A
  • ACNT N/A
  • P/E Ratio
  • CTNM N/A
  • ACNT N/A
  • Revenue Growth
  • CTNM N/A
  • ACNT 5.04
  • 52 Week Low
  • CTNM $3.35
  • ACNT $8.16
  • 52 Week High
  • CTNM $21.58
  • ACNT $13.70
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • ACNT 54.08
  • Support Level
  • CTNM N/A
  • ACNT $12.70
  • Resistance Level
  • CTNM N/A
  • ACNT $13.16
  • Average True Range (ATR)
  • CTNM 0.00
  • ACNT 0.22
  • MACD
  • CTNM 0.00
  • ACNT 0.02
  • Stochastic Oscillator
  • CTNM 0.00
  • ACNT 62.26

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About ACNT Ascent Industries Co.

Ascent Industries Co is engaged in the chemical and metal industry. The group operates into two reportable segments namely the Specialty Chemicals and Tubular Products. The Tubular Products segment serves markets through pipe and tube and customers in the appliance, architectural, automotive, and commercial transportation, brewery, chemical, petrochemical, and other industries. The Specialty Chemicals segment produces specialty products for pulp and paper, coatings, adhesives, sealants, and elastomers (CASE), textile, automotive, household, and other industries. It manufactures welded pipe and tube, majorly from stainless steel, duplex, and nickel alloys. The company also produces specialty chemicals and dyes used in various end markets.

Share on Social Networks: